Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Matthew G Butler"'
Autor:
Aniket V Gore, Brett Athans, James R Iben, Kristin Johnson, Valya Russanova, Daniel Castranova, Van N Pham, Matthew G Butler, Lisa Williams-Simons, James T Nichols, Erica Bresciani, Bejamin Feldman, Charles B Kimmel, Paul P Liu, Brant M Weinstein
Publikováno v:
eLife, Vol 5 (2016)
During embryonic development, cell type-specific transcription factors promote cell identities, while epigenetic modifications are thought to contribute to maintain these cell fates. Our understanding of how genetic and epigenetic modes of regulation
Externí odkaz:
https://doaj.org/article/d49e94f6588e42b886215463aa573ada
Autor:
Eun-Ang, Raiber-Moreau, Guillem, Portella, Matthew G, Butler, Omoshile, Clement, Yves, Konigshofer, James, Hadfield
Publikováno v:
Genes, Chromosomes and Cancer. 62:121-130
Tumor mutational burden (TMB), measured by exome or panel sequencing of tumor tissue or blood (bTMB), is a potential predictive biomarker for treatment benefit in patients with various cancer types receiving immunotherapy targeting checkpoint pathway
Autor:
Dana Ruminski Lowe, Benedicta Forson, Maria Cowen, Matthew G. Butler, Yves Konigshofer, Melissa Berenger, Krystyna Nahlik, Dianren Xia, Catherine Huang, Russell Garlick, Bharathi Anekella
Publikováno v:
Cancer Research. 83:6109-6109
Mutations in the tumor suppressor BRCA1 and BRCA2 genes can cause cell damage that significantly increases the risk of developing breast, ovarian, prostate, and pancreatic cancers. Large genomic rearrangements (LGRs) are defined as deletions, duplica
Abstract 6110: Multi-site evaluation of FFPE homologous recombination deficiency reference materials
Autor:
Dana Ruminski Lowe, Robert M. Whiting, Matthew G. Butler, Yves Konigshofer, Catherine Huang, Indira Chivukula, Krystyna Nahlik, Dianren Xia, Russell Garlick, Bharathi Anekella
Publikováno v:
Cancer Research. 83:6110-6110
Homologous recombination deficiency (HRD) arises when defects in DNA repair pathways occur, leading to genomic instability. HRD status is an emerging therapeutic biomarker; NGS assays that measure it can be used to stratify ovarian and breast cancer
Autor:
Yves Konigshofer, Matthew G. Butler, Krystyna Nahlik, Dana Ruminski Lowe, Catherine Huang, Omoshile Clement, Russell K. Garlick
Publikováno v:
Cancer Research. 82:1024-1024
Here we present data on the characterization and implementation of a set of reference materials for the standardization of homologous recombination deficiency (HRD) assessment. The safety and effectiveness profile of a drug can be improved by using i
Publikováno v:
Cancer Research. 82:3376-3376
Here we describe new reference materials (RMs) for liquid biopsies that are designed to mimic the methylation found in circulating cell-free DNA (ccfDNA). Methylation is an important epigenetic modification that influences cellular differentiation an
Autor:
Laura M, Pillay, Joseph J, Yano, Andrew E, Davis, Matthew G, Butler, Megan O, Ezeude, Jong S, Park, Keith A, Barnes, Vanessa L, Reyes, Daniel, Castranova, Aniket V, Gore, Matthew R, Swift, James R, Iben, Madeleine I, Kenton, Amber N, Stratman, Brant M, Weinstein
Publikováno v:
Angiogenesis. 25(3)
The small monomeric GTPase RHOA acts as a master regulator of signal transduction cascades by activating effectors of cellular signaling, including the Rho-associated protein kinases ROCK1/2. Previous in vitro cell culture studies suggest that RHOA c
Autor:
Iben, Matthew R. Swift, Aniket V. Gore, Pillay Lm, Davis Ae, Matthew G. Butler, Kelly Anne Barnes, Joseph J Yano, Reyes Vl, Amber N. Stratman, Brant M. Weinstein, Daniel Castranova
RationaleThe small monomeric GTPase RHOA acts as a master regulator of signal transduction cascades by activating effectors of cellular signaling, including the Rho-associated protein kinases ROCK1/2. Previousin vitrocell culture studies suggest that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94e2945ac0e33d19439b28bec3e970ce
https://doi.org/10.1101/2021.03.27.437282
https://doi.org/10.1101/2021.03.27.437282
Publikováno v:
Cancer Research. 81:471-471
Immune Checkpoint Inhibitor (ICI) therapies continue to revolutionize treatment of advanced malignancies. However, identification of individuals who respond to ICI treatment remains challenging. Along with programmed death ligand 1(PD-L1 aka CD274) e
Autor:
Jessica Dickens, Rajeswari Vemula, Matthew G. Butler, Catherine Huang, Bharathi Anekella, Omoshile Clement, Yves Konigshofer
Publikováno v:
Cancer Research. 81:2232-2232
Purpose: Whole transcriptome RNA-sequencing (RNA-Seq) has emerged as one of the most effective methods for detection of genomic rearrangements in cancer. Enrichment for poly(A) + RNA as part of library preparation is a standard method to select for m